Colinz Labs

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE923C01011
NSEID:
BSEID: 531210
View on BSE

INR

46.80

1.9 (4.23%)

BSENSE

Mar 19

BSE+NSE Vol: 3.39 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Colinz Labs

Vivanza Biosci.

Beryl Drugs

Unjha Formul.

Zenith Health

Desh Rakshak

Parmax Pharma

Ortin Global

Starsource Multi

Genomic Valley

Saroja Pharma In

Why is Colinz Laboratories Ltd ?

Weak Long Term Fundamental Strength with a -1.13% CAGR growth in Net Sales over the last 5 years

Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of 0.37
The company has been able to generate a Return on Equity (avg) of 4.90% signifying low profitability per unit of shareholders funds

Flat results in Dec 25

ROCE(HY) Lowest at 5.88%

Underperformed the market in the last 1 year

Even though the market (BSE500) has generated returns of 1.22% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -32.68% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Colinz Labs for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Colinz Labs

-32.68%

-0.45

72.61%

Sensex

-1.65%

-0.13

12.27%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-1.13%

EBIT Growth (5y)

3.01%

EBIT to Interest (avg)

0.37

Debt to EBITDA (avg)

0.63

Net Debt to Equity (avg)

-0.68

Sales to Capital Employed (avg)

0.75

Tax Ratio

16.67%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

12.95%

ROE (avg)

4.90%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

1.19

EV to EBIT

5.03

EV to EBITDA

5.03

EV to Capital Employed

1.61

EV to Sales

0.86

PEG Ratio

0.46

Dividend Yield

ROCE (Latest)

7.37%

ROE (Latest)

4.96%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company

NO KEY POSITIVE TRIGGERS

-3What is not working for the Company

ROCE(HY)

Lowest at 5.88%

Loading Valuation Snapshot...